Last night, the FDA approved Vowst, the first orally-administered fecal microbiota product for the prevention of recurrent C. difficile infection. This marks a new milestone for the microbiome field, but most importantly, for patients.
Major congratulations to Seres Therapeutics for this incredible success!
We are beyond excited to see many years of microbiome research turning into real solutions for patient care.
At Clinical Microbiomics, we believe in a world where people are healthier because we understand how to improve our inner ecology – the microbiome.